Urinary Angiogenin as a Marker for Bladder Cancer: A Meta-Analysis.
patients with bladder neoplasm
measurement of angiogenin (ANG) protein in urine
case-control studies
diagnostic role of ANG for early detection of bladder cancer
Abstract
Bladder cancer (BCa) is a common cancer in North America and Europe that carries considerable morbidity and mortality. A reliable biomarker for early detection of the bladder is crucial for improving the prognosis of BCA. In this meta-analysis, we examine the diagnostic role of the angiogenin (ANG) protein in patients' urine with bladder neoplasm. We performed a systematic literature search using ScienceDirect, Web of Science, PubMed/MEDLINE, Scopus, Google Scholar, and Embase, up to 10 Four case-control studies were included with 656 participants (417 cases and 239 controls) in this meta-analysis. The pooled sensitivity of 0.71 (95% CI: 0.66-0.75), specificity of 0.78 (95% CI: 0.73-0.81), LR This meta-analysis showed that ANG could be a fair biomarker for the diagnosis of BCa patients.